Karel Pavelká

43.7k total citations · 9 hit papers
374 papers, 19.7k citations indexed

About

Karel Pavelká is a scholar working on Rheumatology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Karel Pavelká has authored 374 papers receiving a total of 19.7k indexed citations (citations by other indexed papers that have themselves been cited), including 253 papers in Rheumatology, 67 papers in Immunology and 62 papers in Pathology and Forensic Medicine. Recurrent topics in Karel Pavelká's work include Rheumatoid Arthritis Research and Therapies (164 papers), Spondyloarthritis Studies and Treatments (60 papers) and Autoimmune and Inflammatory Disorders Research (53 papers). Karel Pavelká is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (164 papers), Spondyloarthritis Studies and Treatments (60 papers) and Autoimmune and Inflammatory Disorders Research (53 papers). Karel Pavelká collaborates with scholars based in Czechia, United States and Switzerland. Karel Pavelká's co-authors include Ladislav Šenolt, Jiří Vencovský, Ronald van Vollenhoven, Martin Komarc, Michal Tomčík, Maja Špiritović, Hana Štorkánová, Kristýna Bubová, Radim Bečvář and Sabína Oreská and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Karel Pavelká

361 papers receiving 19.0k citations

Hit Papers

Plasma Hsp90 ... 1998 2026 2007 2016 2021 2004 2005 1998 2006 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study
    2021 4.1k citations Hana Štorkánová, Sabína Oreská et al. Scientific Reports profile →
  2. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
    2004 1.4k citations Karel Pavelká et al. The Lancet profile →
  3. The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
    2005 1.4k citations Karel Pavelká, Ronald van Vollenhoven et al. profile →
  4. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
    1998 767 citations Paul Emery, Karel Pavelká et al. profile →
  5. Double‐blind randomized controlled clinical trial of the interleukin‐6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate
    2006 601 citations Karel Pavelká, Paul Emery et al. profile →
  6. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
    2013 502 citations Cem Gabay, Paul Emery et al. The Lancet profile →
  7. EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis
    2009 500 citations Karel Pavelká et al. Annals of the Rheumatic Diseases profile →
  8. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty‐two–week, phase III, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study
    2008 465 citations Ronald van Vollenhoven, Paul Emery et al. profile →
  9. FRI0298 The Impact of DMARD Co-Therapy on Abatacept Effectiveness in Rheumatoid Arthritis Patients. A Pan-European Analysis of RA Registries
    2014 285 citations Juan J. Gómez‐Reino, E. Lie et al. Annals of the Rheumatic Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Karel Pavelká Czechia 56 10.8k 3.7k 3.7k 2.6k 1.8k 374 19.7k
Young Ho Lee South Korea 64 4.8k 0.4× 1.4k 0.4× 4.3k 1.2× 4.3k 1.7× 812 0.4× 1.0k 19.6k
Kazuhiko Yamamoto Japan 78 6.8k 0.6× 2.3k 0.6× 8.7k 2.4× 5.5k 2.1× 1.5k 0.8× 772 25.1k
John D. Isaacs United Kingdom 69 6.1k 0.6× 2.4k 0.6× 6.0k 1.6× 2.4k 0.9× 1.7k 0.9× 395 16.4k
D. Blöch United States 74 21.1k 2.0× 4.5k 1.2× 5.2k 1.4× 3.5k 1.4× 2.9k 1.6× 238 41.2k
Zhihong Liu China 69 2.5k 0.2× 1.5k 0.4× 2.7k 0.7× 7.2k 2.8× 868 0.5× 1.3k 25.1k
Stephen M. Schwartz United States 95 2.6k 0.2× 1.9k 0.5× 3.2k 0.9× 9.3k 3.6× 920 0.5× 407 30.5k
Jacob George Israel 79 2.8k 0.3× 879 0.2× 4.8k 1.3× 5.6k 2.2× 487 0.3× 623 30.4k
Xuan Zhang China 65 3.1k 0.3× 758 0.2× 5.1k 1.4× 7.9k 3.1× 651 0.4× 868 22.7k
Jiří Vencovský Czechia 45 4.1k 0.4× 932 0.3× 2.8k 0.8× 2.4k 0.9× 709 0.4× 267 12.6k
Graeme Jones Australia 84 13.0k 1.2× 833 0.2× 1.0k 0.3× 3.1k 1.2× 545 0.3× 777 30.7k

Countries citing papers authored by Karel Pavelká

Since Specialization
Citations

This map shows the geographic impact of Karel Pavelká's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karel Pavelká with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karel Pavelká more than expected).

Fields of papers citing papers by Karel Pavelká

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karel Pavelká. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karel Pavelká. The network helps show where Karel Pavelká may publish in the future.

Co-authorship network of co-authors of Karel Pavelká

This figure shows the co-authorship network connecting the top 25 collaborators of Karel Pavelká. A scholar is included among the top collaborators of Karel Pavelká based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karel Pavelká. Karel Pavelká is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Elišák, Martin, et al.. (2025). Elevated serum neurofilament light chain levels in patients with neuropsychiatric systemic lupus erythematosus: a cross-sectional study. Lupus Science & Medicine. 12(1). e001309–e001309. 2 indexed citations
2.
Deodhar, Atul, Jerzy Supronik, Alan Kivitz, et al.. (2024). Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From a Randomized, Placebo‐Controlled, Phase 3 Study. Arthritis & Rheumatology. 77(2). 163–170. 1 indexed citations
3.
Cerezo, Lucie Andrés, Jiří Baloun, David Veigl, et al.. (2024). IL-40 is up-regulated in the synovial fluid and cartilage of osteoarthritis patients and contributes to the alteration of chondrocytes phenotype in vitro. Arthritis Research & Therapy. 26(1). 146–146. 4 indexed citations
4.
Heřmánková, Barbora, Maja Špiritović, Sabína Oreská, et al.. (2023). Effect of an 8-Week Tailored Physiotherapy Program on Sexual Health in Women with Scleroderma and Myositis: A Controlled Pilot Study. Rheumatology and Therapy. 10(4). 1089–1105. 1 indexed citations
5.
Friedecký, David, Radana Brumarová, Markéta Pavlı́ková, et al.. (2023). Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment. Arthritis Research & Therapy. 25(1). 234–234. 22 indexed citations
6.
Hánová, Petra, Klára Prajzlerová, H. Mann, et al.. (2023). POS0911 ULTRASOUND-DETECTED SYNOVITIS AMONG INDIVIDUALS AT RISK OF RHEUMATOID ARTHRITIS INCREASES THE RISK OF DEVELOPING CLINICAL ARTHRITIS IN THE FUTURE. Annals of the Rheumatic Diseases. 82. 764–764. 1 indexed citations
7.
Špiritović, Maja, Barbora Heřmánková, Sabína Oreská, et al.. (2021). The effect of a 24-week training focused on activities of daily living, muscle strengthening, and stability in idiopathic inflammatory myopathies: a monocentric controlled study with follow-up. Arthritis Research & Therapy. 23(1). 173–173. 16 indexed citations
8.
Prajzlerová, Klára, Olga Kryštůfková, Petra Hánová, et al.. (2021). High miR-451 expression in peripheral blood mononuclear cells from subjects at risk of developing rheumatoid arthritis. Scientific Reports. 11(1). 4719–4719. 13 indexed citations
9.
Štorkánová, Hana, Sabína Oreská, Maja Špiritović, et al.. (2021). Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study. Scientific Reports. 11(1). 1–1. 4074 indexed citations breakdown →
10.
Bubová, Kristýna, Šárka Forejtová, Markéta Hušáková, et al.. (2019). Cross-sectional study of patients with axial spondyloarthritis fulfilling imaging arm of ASAS classification criteria: baseline clinical characteristics and subset differences in a single-centre cohort. BMJ Open. 9(4). e024713–e024713. 12 indexed citations
11.
Cerezo, Lucie Andrés, Hana Hulejová, Barbora Šumová, et al.. (2019). Pro-inflammatory S100A11 is elevated in inflammatory myopathies and reflects disease activity and extramuscular manifestations in myositis. Cytokine. 116. 13–20. 22 indexed citations
12.
Stibůrková, Blanka, Kateřina Pavelcová, Jakub Závada, et al.. (2017). Functional non-synonymous variants of ABCG2 and gout risk. Lara D. Veeken. 56(11). 1982–1992. 63 indexed citations
13.
14.
Chatzidionysiou, Katerina, E. Lie, Merete Lund Hetland, et al.. (2012). Seropositivity and response to RTX: Data from the CERERRA collaboration. Annals of the Rheumatic Diseases. 71.
15.
Peterfy, Charles, Paul Emery, Mikkel Østergaard, et al.. (2011). Rituximab (RTX) plus Methotrexate (MTX) prevents bone erosion and joint-space narrowing (JSN) and reduces synovitis, osteitis as shown on MRI: Results from a randomised, placebo-controlled trial in patients (PTS) with rheumatoid arthritis (RA-score). Annals of the Rheumatic Diseases. 70. 16 indexed citations
16.
Rùzicková, Š, Ladislav Šenolt, J Gatterová, Jiří Vencovský, & Karel Pavelká. (2008). The Lack of Correlation between the Increased Frequency of Allele IL-1RN*2 of Interleukin-1 Receptor Antagonist Gene in Czech Patients with Knee Osteoarthritis and the Markers of Cartilage Degradation. Folia Biologica. 54(4). 115–120. 5 indexed citations
17.
Combe, B., Ugo Fiocco, M. Gaubitz, et al.. (2007). Double-blind comparison of etanercept and sulfasalazine, alone and combined in active RA patients. Document Server@UHasselt (UHasselt). 2 indexed citations
18.
Fleischmann, R, et al.. (2005). Preliminary efficacy results of rituximab retreatment in patients with active rheumatoid arthritis. Queensland's institutional digital repository (The University of Queensland). 52(9). 7 indexed citations
19.
Chiorazzi, Nicholas, Robert G. Lahita, Karel Pavelká, & Manlio Ferrarini. (1997). B lymphocytes and autoimmunity. New York Academy of Sciences eBooks. 2 indexed citations
20.
Pavelká, Karel, et al.. (1977). [A new nonsteroid antirheumatic drug diclofenac in the treatment of rheumatoid arthritis (preliminary report].. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 55(6). 355–9. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Young Ho Lee Breakdown of academic impact, for papers by Kazuhiko Yamamoto Breakdown of academic impact, for papers by John D. Isaacs Breakdown of academic impact, for papers by D. Blöch Breakdown of academic impact, for papers by Zhihong Liu Breakdown of academic impact, for papers by Stephen M. Schwartz Breakdown of academic impact, for papers by Jacob George Breakdown of academic impact, for papers by Xuan Zhang Breakdown of academic impact, for papers by Jiří Vencovský Breakdown of academic impact, for papers by Graeme Jones
Rankless by CCL
2026